Logo image of PSTV

PLUS THERAPEUTICS INC (PSTV) Stock Fundamental Analysis

NASDAQ:PSTV - Nasdaq - US72941H5090 - Common Stock - Currency: USD

1.2  +0 (+0.01%)

Fundamental Rating

1

PSTV gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of PSTV have multiple concerns. While showing a medium growth rate, PSTV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

PSTV had negative earnings in the past year.
PSTV had a negative operating cash flow in the past year.
PSTV had negative earnings in each of the past 5 years.
PSTV had a negative operating cash flow in each of the past 5 years.
PSTV Yearly Net Income VS EBIT VS OCF VS FCFPSTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

PSTV has a worse Return On Assets (-184.65%) than 89.34% of its industry peers.
Industry RankSector Rank
ROA -184.65%
ROE N/A
ROIC N/A
ROA(3y)-87.62%
ROA(5y)-76.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSTV Yearly ROA, ROE, ROICPSTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500

1.3 Margins

PSTV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSTV Yearly Profit, Operating, Gross MarginsPSTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

0

2. Health

2.1 Basic Checks

PSTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PSTV has more shares outstanding
Compared to 5 years ago, PSTV has more shares outstanding
The debt/assets ratio for PSTV is higher compared to a year ago.
PSTV Yearly Shares OutstandingPSTV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
PSTV Yearly Total Debt VS Total AssetsPSTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -105.14, we must say that PSTV is in the distress zone and has some risk of bankruptcy.
PSTV's Altman-Z score of -105.14 is on the low side compared to the rest of the industry. PSTV is outperformed by 97.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -105.14
ROIC/WACCN/A
WACC8.75%
PSTV Yearly LT Debt VS Equity VS FCFPSTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

PSTV has a Current Ratio of 0.44. This is a bad value and indicates that PSTV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of PSTV (0.44) is worse than 93.96% of its industry peers.
A Quick Ratio of 0.44 indicates that PSTV may have some problems paying its short term obligations.
PSTV has a worse Quick ratio (0.44) than 93.78% of its industry peers.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.44
PSTV Yearly Current Assets VS Current LiabilitesPSTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.95% over the past year.
PSTV shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.67%.
Measured over the past years, PSTV shows a decrease in Revenue. The Revenue has been decreasing by -5.87% on average per year.
EPS 1Y (TTM)63.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63%
Revenue 1Y (TTM)52.67%
Revenue growth 3Y153.95%
Revenue growth 5Y-5.87%
Sales Q2Q%17.42%

3.2 Future

PSTV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.
The Revenue is expected to grow by 73.83% on average over the next years. This is a very strong growth
EPS Next Y59.58%
EPS Next 2Y29.02%
EPS Next 3Y18.39%
EPS Next 5Y16.26%
Revenue Next Year36.65%
Revenue Next 2Y1.5%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.83%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PSTV Yearly Revenue VS EstimatesPSTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
PSTV Yearly EPS VS EstimatesPSTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -500K -1M -1.5M -2M -2.5M

0

4. Valuation

4.1 Price/Earnings Ratio

PSTV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PSTV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSTV Price Earnings VS Forward Price EarningsPSTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSTV Per share dataPSTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PSTV's earnings are expected to grow with 18.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.02%
EPS Next 3Y18.39%

0

5. Dividend

5.1 Amount

PSTV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PLUS THERAPEUTICS INC

NASDAQ:PSTV (2/21/2025, 8:00:01 PM)

1.2

+0 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners8.46%
Inst Owner Change-99.98%
Ins Owners2.55%
Ins Owner Change26.56%
Market Cap7.08M
Analysts82
Price Target10.46 (771.67%)
Short Float %1.59%
Short Ratio2.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.96%
Min EPS beat(2)-3.59%
Max EPS beat(2)35.51%
EPS beat(4)3
Avg EPS beat(4)21.92%
Min EPS beat(4)-3.59%
Max EPS beat(4)35.51%
EPS beat(8)5
Avg EPS beat(8)10.25%
EPS beat(12)7
Avg EPS beat(12)6.66%
EPS beat(16)8
Avg EPS beat(16)0.3%
Revenue beat(2)0
Avg Revenue beat(2)-15.52%
Min Revenue beat(2)-25.16%
Max Revenue beat(2)-5.88%
Revenue beat(4)1
Avg Revenue beat(4)-3.12%
Min Revenue beat(4)-25.16%
Max Revenue beat(4)21.13%
Revenue beat(8)2
Avg Revenue beat(8)-1.16%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-75.79%
EPS NQ rev (1m)26.85%
EPS NQ rev (3m)29.46%
EPS NY rev (1m)0%
EPS NY rev (3m)19.42%
Revenue NQ rev (1m)-11.42%
Revenue NQ rev (3m)-21.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.52
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS0.97
BVpS-0.88
TBVpS-1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -184.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-87.62%
ROA(5y)-76.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.14%
Cap/Sales 12.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.44
Quick Ratio 0.44
Altman-Z -105.14
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)47.58%
Cap/Depr(5y)56.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63%
EPS Next Y59.58%
EPS Next 2Y29.02%
EPS Next 3Y18.39%
EPS Next 5Y16.26%
Revenue 1Y (TTM)52.67%
Revenue growth 3Y153.95%
Revenue growth 5Y-5.87%
Sales Q2Q%17.42%
Revenue Next Year36.65%
Revenue Next 2Y1.5%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.83%
EBIT growth 1Y2.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.99%
OCF growth 3YN/A
OCF growth 5YN/A